Title: Comparative Study: CPX-351 Shows Reduced Cardiotoxicity Compared to Daunorubicin plus Cytarabine Free-Drug Combination in hiPSC-Derived Cardiomyocytes in vitro
Introduction:
Cardiotoxicity, or the potential damage to the heart caused by certain drugs, is a significant concern in cancer treatment. Anthracyclines, such as daunorubicin, and cytarabine are commonly used chemotherapeutic agents for the treatment of acute myeloid leukemia (AML). However, their use is limited due to their potential cardiotoxic effects. In recent years, a novel liposomal formulation called CPX-351 has emerged as a promising alternative for AML treatment. This article aims to discuss a comparative study that demonstrates the reduced cardiotoxicity of CPX-351 compared to the daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
Understanding Cardiotoxicity:
Cardiotoxicity refers to the adverse effects of drugs on the heart, which can range from mild abnormalities in cardiac function to severe conditions such as heart failure. Anthracyclines, including daunorubicin, are known to cause cardiotoxicity by generating reactive oxygen species (ROS) and inducing oxidative stress, leading to damage to cardiac cells. Cytarabine, on the other hand, can cause cardiotoxicity by disrupting DNA synthesis and impairing mitochondrial function.
The Promise of CPX-351:
CPX-351 is a liposomal formulation that encapsulates daunorubicin and cytarabine in a fixed 5:1 molar ratio. This unique formulation allows for the targeted delivery of both drugs to leukemic cells while minimizing exposure to healthy tissues, including the heart. Previous clinical trials have shown that CPX-351 improves overall survival and reduces the incidence of cardiotoxicity compared to the free-drug combination in AML patients.
The Comparative Study:
To further investigate the reduced cardiotoxicity of CPX-351, researchers conducted a comparative study using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in vitro. hiPSC-CMs are a valuable tool for studying drug-induced cardiotoxicity as they closely resemble human cardiac cells.
In the study, hiPSC-CMs were exposed to CPX-351 and the daunorubicin plus cytarabine free-drug combination at clinically relevant concentrations. The researchers assessed various parameters related to cardiotoxicity, including cell viability, mitochondrial function, and the generation of ROS.
Results and Findings:
The study revealed that hiPSC-CMs treated with CPX-351 exhibited significantly higher cell viability compared to those treated with the free-drug combination. This suggests that CPX-351 is less toxic to cardiac cells and better preserves their viability.
Furthermore, CPX-351-treated hiPSC-CMs showed improved mitochondrial function compared to cells treated with the free-drug combination. Mitochondria are crucial for energy production in cardiac cells, and their impairment can lead to cardiotoxicity. The findings indicate that CPX-351 has a lesser impact on mitochondrial function, potentially reducing the risk of cardiotoxicity.
Moreover, the generation of ROS was significantly lower in hiPSC-CMs treated with CPX-351 compared to the free-drug combination. ROS play a key role in anthracycline-induced cardiotoxicity, and the reduced ROS production suggests that CPX-351 may mitigate oxidative stress and subsequent damage to cardiac cells.
Conclusion:
The comparative study using hiPSC-derived cardiomyocytes in vitro provides compelling evidence that CPX-351 exhibits reduced cardiotoxicity compared to the daunorubicin plus cytarabine free-drug combination. These findings support the clinical observations of improved cardiac safety with CPX-351 in AML patients. The liposomal formulation of CPX-351 allows for targeted drug delivery, minimizing exposure to healthy cardiac cells while effectively treating leukemia. Further research and clinical trials are warranted to validate these findings and explore the potential of CPX-351 as a safer alternative for AML treatment.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/lower-cardiotoxicity-of-cpx-351-relative-to-daunorubicin-plus-cytarabine-free-drug-combination-in-hipsc-derived-cardiomyocytes-in-vitro-scientific-reports/